The World Health Organization-led Paediatric Antiretroviral Drug Optimization (PADO) group establishes and reviews priorities for drug development, and set the foundation for GAP-f in the areas of paediatric HIV treatment and prevention. This consortium’s latest development included how to overcome barriers to newer, optimized pediatric ARV formulations for immediate and widely-accessed use in countries with high HIV burden.